Introduction

Labour is the physiologic process by which a fetus is expelled from the uterus. It requires the presence of regular painful uterine contractions, which increase in frequency, intensity and duration leading to progressive cervical effacement and dilatation. In normal labour, there appears to be a time-dependent relationship between these elements: The biochemical connective tissue changes in the cervix usually precede uterine contractions that, in turn, lead to cervical dilatation. All of these events culminate in spontaneous rupture of the fetal membranes. The mean duration of human singleton pregnancy is 280 days (40 weeks) from the first day of the last normal menstrual period. “Term” is defined as the period from 37.0 to 42.0 weeks of gestation. Preterm birth (defined as delivery before 37 weeks’ gestation) and post-term pregnancy (defined as pregnancy continuing beyond 42 weeks) is both associated with a significant increase in perinatal morbidity and mortality.

Studies in animals have underlined the importance of fetus in control of timing of labor. Activated fetal hypothalamic-pituitary-adrenal (HPA) axis leads to a surge in adrenal cortisol production. Fetal cortisol stimulates activity of placental 17α-hydroxylase/17, 20 lyase (CYP 17) enzyme, which catalyzes the conversion of pregnenolone to estradiol. The altered ratio of progesterone: estrogen in favor of later, up regulates the synthesis of uterine prostaglandins (PG) and labour. Human placenta lacks CYP 17 and as such, the mechanism of labour is different.

Parturition in most animals results from changes in circulating hormone levels in the maternal and fetal circulations at the end of pregnancy (endocrine events), whereas labour in humans results from a complex dynamic biochemical dialog that exists between the fetoplacental unit and the mother (paracrine and autocrine events).
**Steps in Parturition**

In pregnancy there is a dynamic balance between the forces that cause uterine quiescence and the forces that produce coordinated uterine contractility. There is also a balance between the forces that keep the cervix closed to prevent uterine emptying and the forces that soften the cervix and allow it to dilate. For delivery to occur, both balances must be tipped in favor of active uterine emptying. Many of the elements in this parturition complex elaborate feed forward characteristics. Labour at term is physiologically regarded as a release from the inhibitory effects of pregnancy on myometrium. Human labour at term is a multifactorial physiologic event involving integrity of complementary endocrine, paracrine and autocrine factors leading to gradual changes within maternal uterine tissues (myometrium, deciduas and uterine cervix).

For parturition to occur, two changes must take place in a woman’s reproductive tract. First, the uterus must be converted from a quiescent structure with dyssynchronous contractions to an active co-ordinately contracting organ with complex interlaced muscular components resulting in regular phasic uterine contractions. This requires the formation of gap junctions between myometrial cells to allow for transmission of the contractile signal. The fetus may coordinate this switch in myometrial activity through its influence on placental steroid hormone production, through the mechanical distention of the uterus and through the secretion of neurohypophyseal hormones and other stimulators of prostaglandin synthesis. The second change is that the cervical connective tissue and smooth muscle must be capable of dilatation to allow the passage of the fetus from the uterus. These changes are accompanied by shift from progesterone to estrogen dominance, increased responsiveness to oxytocin by means of up regulation of myometrial oxytocin receptor, increased PG synthesis in uterus, increased myometrial gap junction formation, decreased nitric oxide (NO) activity and increased influx of calcium into myocytes with ATP dependent binding of myosin to actin, increased endothelin leading to augmented uterine blood flow and myometrial activity. Figure 1. The final common pathway toward labour appears to be the activation of the fetal HPA axis and is probably common to all viviparous species. Complementary changes in the cervix involving a decrease in progesterone dominance and the actions of prostaglandins and relaxin, via connective tissue alterations, collagenolysis, and a decrease in collagen stabilization through metalloproteinase inhibitors, lead to cervical softening and dilation.

**Excitability in Uterine Smooth Muscles and Coordination of Myometrial Contractility; Role of Hormones**

Transformation of uterine myometrium from a state of quiescence to coordinated muscle contraction, involves changes in the density and activity of ion channels and pumps, and of gap junctions, which facilitate the spread of activity throughout the muscle cells in the uterine wall. These changes are achieved by local and circulating hormones in the lead up to labour, a process that has been termed ‘activation’. The contractility of myometrium is heralded by origin of action potentials (AP) with subsequent spread among muscle fibres. The APs consist of both simple spikes and complex forms. Simple spikes in human myometrium are attributed to L-type calcium channels, transient sodium channels and rapidly activating and inactivating calcium channels. Complex APs consist of simple spikes followed by a sustained plateau of depolarization. This form of AP is most conspicuous in inner layer and upper segment (fundus) of uterus and occurs throughout 3rd trimester and during labour. Duration of plateau dictates the duration of contraction. Rapid propagation of AP throughout the uterus is mediated by action potential calcium wave hypothesis. Key elements of this hypothesis include the following:

1. APs propagate through the uterus and initiate intercellular calcium waves. This step synchronizes the initiation of the contraction through the thickness of the wall and among all regions of the uterus.
2. Following initiation by an AP, an intercellular calcium wave propagates through each bundle and individual myocytes contract as the wave passes. Calcium waves do not cross boundaries between bundles. Either
functional gap junctions or paracrine signalling mechanisms are required for intercellular calcium wave propagation.

3. Electrical activity is not required for the direct recruitment of myocytes for contraction; however, gap junction function is essential for the action potential to propagate through each bundle in the uterus. The proportion of myocytes that contract as a direct result of experiencing the initiating action potential could be very small (<1%).

4. Each myocyte remains contracted as long as the [Ca\(^{2+}\)]\(_{i}\) remains elevated, the duration of which is determined by the calcium metabolism of each individual cell.

Prostaglandin F2α and oxytocin increase the opening of L-type calcium channels in response to depolarization. Estrogen is involved in the change in the form of AP to complex forms. Oxytocin enhances the plateau component of complex APs leading to gradual increase in duration of contractions as gestation ends\(^{[19]}\) [Figure 2].

**MYOMETRIAL ACTIVATION DURING LABOUR**

Trigger for onset of labour comprises a fetal endocrine cascade involving the fetal H-P-A axis which, in most species, leads to an increase in estrogen and decrease in progesterone in maternal plasma.\(^{[20]}\) This endocrine cascade ultimately leads to both the ‘activation’ (contraction-associated protein (CAP) expression) and the ‘stimulation’ of the myometrium through the increased production of uterotonics such as oxytocin and stimulatory prostaglandins [Figure 3]. Activation is associated with increased expression of the gap junction protein, connexin-43(Cx-43) as well as the oxytocin receptor (OTR) and prostaglandin F receptor. Expression of these CAPs is regulated positively by estrogen and negatively by progesterone, and CAP expression is increased in preterm labour but does not increase when labour is blocked by progesterone.\(^{[21]}\) Expression of other CAPs such as the sodium channel and calcium channel is also increased close to term. Other putative CAPs are expressed in the uterus, including enzymes that regulate uterotonin levels (e.g., oxytocin endopeptidase and cyclooxygenase), proteins which interact with actin/myosin (e.g., MLCK, calmodulin), other uterotonin receptors (e.g., endothelin, thromboxane A2, α-adrenergic and potassium channels, however, there is no strong evidence to link their expression in the myometrium with the onset of term or preterm labour.

Estrogen increases transcription of the Cx-43 and OTR genes. Estrogen also significantly increases the levels of mRNA encoding the AP-1 protein, c-fos in the myometrium that precedes the increased expression of Cx-43. The onset of term and preterm labour in the rat is associated with increased expression of c-fos and the fos family members fra-1 and fra-2, and Cx-43 and expression of these genes is attenuated when labour is blocked by progesterone.

progesterone, a critical pregnancy-maintaining hormone, can

---

**Figure 2:** Parturition cascade leading to labour induction at term. The induction of labour at term is regulated by paracrine and autocrine factors acting in coordination to promote uterine contraction. COX-2: Cyclooxygenase 2, OT: Oxytocin, PGDH: Prostaglandin dehydrogenase, PGEM: 13, 14-dihydro-15-keto-PGE2, PGFM: 13, 14-dihydro-15-keto-PGF2α, PLA2: Phospholipase A, SROM: Spontaneous rupture of the fetal membranes, 11β-HSD: 11β-hydroxysteroid dehydrogenase, 16-OH DHEAS: 16-hydroxydehydroepiandrosterone sulfate

**Figure 3:** Dual pathway by which the fetal genome controls the onset of labour through endocrine and mechanical signals. HPA-Hypothalamic Pituitary Adrenal, P-progesterone, E-estrogen
block stretch-induced gene expression in the myometrium and maintain myometrial growth post-term.\textsuperscript{[22]}

Now let us review the role of different hormones in parturition, in detail

**Corticotropin Releasing Hormone**

Corticotropin releasing hormone (CRH) is a peptide hormone released by the hypothalamus but is also expressed by placental and chorionic trophoblasts and amniotic and decidual cells.\textsuperscript{[23-28]} In fact from second trimester (16\textsuperscript{th} week onwards), the placenta is the major source of CRH secretion.\textsuperscript{[23]} CRH stimulates pituitary ACTH secretion and adrenal cortisol production. In the mother, cortisol inhibits hypothalamic CRH and pituitary ACTH release, creating a negative feedback loop. In contrast, cortisol stimulates CRH release by the decidual, trophoblastic, and fetal membranes.\textsuperscript{[25-28]} CRH, in turn, further drives maternal and fetal HPA activation, thereby establishing a potent positive feed-forward loop. In normal pregnancy, the increased production of CRH from decidual, trophoblastic, and fetal membranes leads to an increase in circulating cortisol beginning in midgestation.\textsuperscript{[29]}

The effects of CRH are enhanced by a fall in maternal plasma CRH-binding protein near term.\textsuperscript{[190]} Activation of the fetal HPA axis results in enhanced fetal pituitary adrenocorticotropin hormone (ACTH) secretion that leads, in turn, to the release of abundant C19 estrogen precursor dehydroepiandrosteredione sulfate (DHEAS) from the intermediate (fetal) zone of the fetal adrenal [Figure 2]. This is because the human placenta is an incomplete steroidogenic organ and estrogen synthesis by the human placenta has an obligate need for C19 steroid precursor [Figure 2].\textsuperscript{[31]} DHEAS is converted in the fetal liver to 16-hydroxy DHEAS and then travels to the placenta where it is metabolized into estradiol (E2), estrone (E1), and estriol (E3). The action of estrogen is likely paracrine-autocrine.\textsuperscript{[32,33]} In addition to DHEAS, the fetal adrenal glands also produce copious amounts of cortisol. Cortisol acts to prepare fetal organ systems (by fetal lung maturation) for extrauterine life and to promote expression of a number of placental genes, including corticotropin releasing hormone (CRH), oxytocin, and prostaglandins (especially prostaglandin E2 [PGE2]). CRH also enhances prostaglandin production by amniotic, chorionic, and decidual cells.\textsuperscript{[29]} Prostaglandins, in turn, stimulate CRH release from the decidual and fetal membranes.\textsuperscript{[26]} The rise in prostaglandins ultimately results in parturition.\textsuperscript{[34] CRH also can directly affect myometrial contractility.\textsuperscript{[35]} Other actions of CRH include dilation of the uterine vessels and stimulation of smooth muscle contractions, dilation of the fetal placental vessels via NO synthetase activation; and stimulation of prostaglandins F2\textalpha and E2 production by fetal membranes and decidua.\textsuperscript{[36-38]} These are all actions conducive to the initiation of labour. CRH is also stimulated by inflammatory cytokines.\textsuperscript{[39]}

**Estrogen**

Pregnancy is a hyperestrogenic state. The placenta is the primary source of estrogen and concentration of estrogen increases with progressing gestational age. The human placenta lacks CYP 17, needed for conversion from progesterone to estradiol. The fetal zone of the adrenal gland produces DHEAS, which may be hydroxylated to 16-OH-DHEAS in the fetal liver. The 16-OH-DHEAS may be aromatized by the placenta to produce estradiol, the major circulating estrogen of human pregnancy [Figure 2]. In contrast to the nonpregnant state, during late human pregnancy the ovary is a minor source of circulating estrogens. Estradiol and estrone are synthesized primarily (90\%) by aromatization of maternal C19 androgens (testosterone and androstenedione), whereas estriol is derived exclusively from the fetal C19 estrogen precursor (DHEAS). Estriol concentrations in serum and saliva increase during the last four to six weeks of pregnancy.

Estrogens promote a series of myometrial changes including increased production of PG E2 and PG F2\textalpha with augmented expression of PG receptors,\textsuperscript{[40]} increased receptor expression of oxytocin, \alpha adrenergic agonist which modulate membrane calcium channels,\textsuperscript{[41]} increased synthesis of connexin and gap junction formation in myometrium,\textsuperscript{[42]} up regulation of enzyme responsible for muscle contraction like myosin light chain kinase, calmodulin,\textsuperscript{[43-46]} All these changes allow coordinated uterine contractions.

Cervical ripening may be associated with the down-regulation of the estrogen receptor. The control of the softening of the cervix, which involves rearrangement and realignment of collagen, elastin, and glycosaminoglycans such as decorin, is not well studied and is poorly understood.\textsuperscript{[33]}

**Progestosterone**

Corpus luteum is the source of progesterone till seven weeks of pregnancy. Placenta takes over the function at approximately seven to nine weeks of gestation. In pregnancy progesterone is in dynamic balance with estrogen in the control of uterine activity. Animals demonstrate systemic progesterone withdrawal as an essential component in initiation of labour. Humans though do not show fall in circulating progesterone, there is growing number of
evidence that, spontaneous onset of labour is preceded by a physiologic withdrawal of progesterone activity at the level of uterine receptors.

Progesterone in vitro decreases myometrial contractility and inhibits myometrial gap junction formation. Progesterone activity stimulates the uterine NO synthetase, which is a major factor in uterine quiescence. Progesterone down-regulates prostaglandin production, as well as the development of calcium channels and oxytocin receptors both involved in myometrial contraction. Calcium is necessary for the activation of smooth muscle contraction. In the cervix, progesterone increases tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). TIMP-1 inhibits collagenolysis. Thus, it is clear that progesterone is a major factor in uterine quiescence and cervical integrity. The factors that result in parturition must overcome the progesterone effect that predominates during the early pregnancy period of uterine quiescence. The activity of 17, 20 hydroxysteroid dehydrogenase in fetal membranes increases around the time of parturition, leading to an increase in net 17β-estradiol and 20-dihydroprogesterone. This is a factor in altering the estrogen/progesterone balance. There may be decreased progesterone receptor levels at term resulting in a diminished progesterone effect.

Cortisol and progesterone appear to have antagonistic actions within the fetoplacental unit. For example, cortisol increases prostaglandin production by the placental and fetal membranes by up-regulating cyclooxygenase-2 (amnion and chorion) and down-regulating 15-hydroxyprostaglandin dehydrogenase (15-OH-PGDH) (chorionic trophoblast), thereby promoting cervical ripening and uterine contractions. Progesterone has the opposite effect. In addition, cortisol has been shown to compete with the inhibitory action of progesterone in the regulation of placental CRH gene expression in primary cultures of human placenta. It is likely, therefore, that the cortisol-dominated environment of the fetoplacental unit just before the onset of labour may act through a series of autocrine-paracrine pathways to overcome the efforts of progesterone to maintain uterine quiescence and prevent myometrial contractions.

**Prostaglandins**

Prostaglandins are formed from arachidonic acid that is converted to prostaglandin H2 by the enzyme prostaglandin H synthetase (PGHS). PGHS-2 is an inducible form of the enzyme. Cytokines increase the concentration of this enzyme 80-fold. Prostaglandins are degraded by 15-OH-PGDH. Cyclo-oxygenase-2 (COX-2) is cytokine inducible, is increased by NO. This is another mechanism by which prostaglandin production increases during inflammation.

There is good evidence that prostaglandins are involved in the final pathway of uterine contractility and parturition. Prostacyclins, inhibitory prostaglandins present throughout early pregnancy, are also responsible for uterine quiescence during pregnancy. Although prostaglandins may not be obligatory for labour in knockout mice, they are of major importance in women. Prostaglandins are produced in the placenta and fetal membranes. Prostaglandin levels are increased before and during labour in the uterus and membranes. PGF2α is produced primarily by the maternal decidua and acts on the myometrium to up-regulate oxytocin receptors and gap junctions, thereby promoting uterine contractions. PGE2 is primarily of fetoplacental origin and is likely more important in promoting cervical ripening (maturation) associated with collagen degradation and dilation of cervical small blood vessels and spontaneous rupture of the fetal membranes. Many factors affect the production of prostaglandins. Levels are decreased by progesterone and increased by estrogens. Several interleukins result in an increase in prostaglandin production.

**OTHER FACTORS**

Circulating oxytocin does not increase in labour until after full cervical dilatation. Oxytocin is less effective in causing uterine contractions in mid pregnancy than at term. However, the concentration of uterine oxytocin receptors increases toward the end of pregnancy. This results in increased efficiency of oxytocin action as pregnancy progresses. Estrogen increases oxytocin receptor expression and progesterone suppresses such estrogen-induced increase in cultured human myometrial cells. Oxytocin induces uterine contractions in two ways. Oxytocin stimulates the release of PGE2 and prostaglandin F2α in fetal membranes by activation of phospholipase C. The prostaglandins stimulate uterine contractility. Oxytocin can also directly induce myometrial contractions through phospholipase C (PLC), which in turn activates calcium channels and the release of calcium from intracellular stores. Oxytocin is locally produced in the uterus. The role of this local endogenous oxytocin is unknown.

Relaxin is a peptide hormone that is a member of the insulin family. Relaxin consists of A and B peptide chains linked together by two disulfide bonds. In women, circulating relaxin is a product of the corpus luteum of pregnancy. Circulating relaxin is secreted in a pattern similar to that of human chorionic gonadotropin. That circulating relaxin is not critical for pregnancy maintenance However; relaxin is also a product of the placenta and decidua. Relaxin from these sources, which may act locally, is not secreted into...
Relaxin receptors are present on the human cervix. Some of the effects of relaxin include stimulation of procollagenase and prostromelysin, as well as a decrease in TIMP-1. Relaxin is also capable of inhibiting contractions of non-pregnant human myometrial strips. Paradoxically, relaxin does not inhibit contractions of pregnant human uterine tissue. This may be because of the competitive effects of progesterone.

**Preterm Labor**

Preterm (premature) birth is defined as delivery between 20-37 weeks, it complicates 7%-10% of all deliveries. The causes include intrauterine growth restriction, preeclampsia, placenta previa, premature rupture of membrane, intraamniotic infection and spontaneous. It may reflect a normal break down of the normal mechanisms responsible for maintaining uterine quiescence throughout gestation. Several mechanisms are proposed:

1. Deficiency of choriodecidual 15-OH-PGDH enzyme, responsible for degradation of prostaglandins, leads to increased concentrations of PGE2 which reaches myometrium and initiates contractions.

2. Maternal physical and psychological stress leads to premature activation of the maternal HPA axis and premature release of CRH with resultant programming of placental clock. Chronic hypertension, severe pregnancy induced hypertension, uteroplacental insufficiency is variably associated with stress induced HPA axis activation culminating in preterm labour [Figure 4].

3. Genital infections affecting decidua/amniochorion lead to maternal or fetal inflammatory response. The activated macrophages and granulocytes release inflammatory mediators like cytokines, (IL-1, IL-6 and TNFα), matrix metallo proteinases (MMP) (collagenase, gelatinase, stromelysin) and products of lipooxygenase and cyclooxygenase pathway. Cytokines stimulate PG production and induces MMPs, which further weaken the fetal membranes and ripen the cervix by disrupting the rigid collagen matrix. Cytokine and eicosanoids accelerate each other’s production. TNF-α additionally promotes apoptosis. Infection per se leads to reduction in 15-OH-PDGH enzyme levels aiding in preterm labour. All these mediators ultimately result in premature rupture of membranes and overwhelmed normal parturition cascade leading to preterm labour [Figure 5].

4. Decidual hemorrhage generates thrombin, which is a powerful uterotonic agent. It stimulates myometrial contractions by activated phosphatidyl inositol signaling pathways and also increases expression of plasminogen activator and MMPs [Figure 6].
5. Excessive uterine stretching caused by multiple birth pregnancy/polyhydramnios generates a signal that transmits through cellular cytoskeleton and activates cellular protein kinase. The acute distension also upregulates certain genes including an interferon-stimulated gene encoding a 54-kD protein, the gene for Huntington-interacting protein 2 (an ubiquitin-conjugating enzyme), and a novel as yet unidentified transcript.

6. Higher mid pregnancy CRH levels and a 4 week advancement in the higher levels of salivary or urinary estriol result in preterm labour. Salivary estrogen has been suggested as a screen for the potential of preterm labour risk.

7. Premature birth is associated with increased circulating relaxin levels. Women who have superovulation with human menopausal gonadotrophins for either ovulation induction or in vitro fertilization have a significantly higher risk of premature birth. These women, who have multiple corpora lutea, have significant levels of hyperrelaxinemia. Women destined to have premature delivery have higher levels of relaxin at 30 weeks gestation than women who deliver at term.

**POST TERM PREGNANCY**

Post-term (prolonged) pregnancy is defined as a pregnancy that has extended to or beyond 42 weeks (294 days) from the first day of the last normal menstrual period or 14 days beyond the best obstetric estimate of the date of delivery. The most common cause of prolonged pregnancy is an error in gestational age dating. Risk factors include nulliparity and a previous post-term pregnancy, male fetus. Rarer causes include placental sulfatase deficiency, fetal adrenal insufficiency, or fetal anencephaly. There is a definite underlying biologic or genetic basis, which is not yet clearly defined.

Both the fetus and the mother are at risk. The complications include increased perinatal deaths, infantile death, neonatal encephalitis. Recent consensus opinions recommend the routine induction of labour at an earlier gestation age, specifically 41 weeks’ gestation.

**CONCLUSION**

Labour is a complex physiologic process involving fetal, placental, and maternal signals. A variety of endocrine systems play a role in the maintenance of uterine quiescence and the onset of parturition, with its attendant increase in uterine contractility and cervical ripening. There are many factors that can tip the balance in favor of delivery early, late, or on time. These factors, such as prostaglandins or inflammatory cytokines, may directly affect the contractile mechanisms. Other factors, such as oxytocin, CRH, or relaxin, may indirectly alter the actions of complementary systems. The timely onset of labour and birth is an important determinant of perinatal outcome. Both preterm labour and delivery and post-term pregnancy are associated with increased perinatal morbidity and mortality. It is only with increased understanding of the processes of parturition that obstetric care providers will be able to further improve the safety of the birth process culminating in successful pregnancy outcomes.

**REFERENCES**

1. Liggins GC. Initiation of labor. Biol Neonate 1989;55:366-94.
2. Liggins GC, Fairclough RJ, Grieses SA, Kendall JZ, Knox BS. The mechanism of initiation of parturition in the ewe. Recent Prog Horm Res 1973;29:111-59.
3. Flint AP, Anderson AB, Steele PA, Turnbull AC. The mechanism by which fetal cortisol controls the onset of parturition in the sheep. Biochem Soc Trans 1975;3:1189-94.
4. Thorburn GD, Hollingworth SA, Hooper SB. The trigger for parturition in sheep: Fetal hypothalamus or placenta? J Dev Physiol 1991;15:71-9.
5. Matthews SG, Challis JR. Regulation of the hypothalamo-pituitary-adrenocortical axis in fetal sheep. Trends Endocrinol Metab 1996;7:239-46.
6. Norwitz ER, Robinson JN, Challis JR. The control of labor. N Engl J Med 1999;341:660-6.
7. Challis JR, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000;21:514-50.
8. Lopez Bernal A, Rivera J, Europe-Finner GN, Phaneuf S, Asbóth G. Parturition: activation of stimulatory pathways or loss of uterine quiescence? Adv Exp Med Biol 1995;395:435-51.
9. Garfield RE, Saade G, Buihismesi C, Buihismesi I, Shi L, Shi SQ, et al. Control and assessment of the uterus and cervix during pregnancy and labour. Hum Reprod Update 1998;4:673-95.
10. Sanborn BM. Relationship of ion channel activity to control of myometrial calcium. J Soc Gynecol Invest 2000;7:4-11.
11. Pauerstein CJ, Zauder HL. Autonomic innervation, sex steroids and uterine contractility. Obstet Gynecol Surv 1970;25:617-30.
12. Masaki T. Endothelins: Homeostatic and compensating action in the circulating and endocrine system. Endocr Rev 1993;14:256-68.
13. Leppert PC. Anatomy and physiology of cervical ripening. Clin Obstet Gynecol 1995;38:267-79.
14. Challis JR, Lye SJ. Parturition. In: Knobil E, Neill JD, editors. The Physiology of Reproduction. 2nd ed. New York: Raven Press; 1994. p. 985-1031.
15. Inoue Y, Nakao K, Okabe K, Izumi H, Kanda S, Kitamura K, et al. Some electrical properties of human pregnant myometrium. Am J Obstet Gynecol 1990;162:1090-8.
16. Parkington HC, Tonta MA, Brennecke SP, Coleman HA. Contractile activity, membrane potential, and cytoplasmic calcium in human uterine smooth muscle in the third trimester of pregnancy and during labor. Am J Obstet Gynecol 1999;181:1445-51.
17. Parkington HC, Tonta MA, Davies NK, Brennecke SP, Coleman HA. Hyperpolarization and slowing of the rate of contraction in human uterus in pregnancy by prostaglandins E2 and F2alpha: Involvement of the Na+pump. J Physiol 1999;514:229-43.
18. Nakao K, Inoue Y, Okabe K, Kawarabayashi T, Kitamura K. Oxytocin...
enhances action potentials in pregnant human myometrium – A study with microelectrodes. Am J Obstet Gynecol 1997;177:222-8.

19. Young RC. A computer model of uterine contractions based on action potential propagation and intercellular calcium waves. Obstet Gynecol 1997;89:604-8.

20. Challis JR, Lyu SJ. Parturition. In: Knobil E, Neil JD, editors. The Physiology of Reproduction. New York: Raven Press; 1994. p. 985-1031.

21. Gardner MO, Goldenberg RL, Cliver SP, Tucker JM, Nelson KG, et al. The origin and outcome of preterm twin pregnancies. Obstet Gynecol 1995;85:553-7.

22. Lyu SJ, Ou CW, Teoh TG, Erb G, Stevens Y, Casper R, et al. The molecular basis of labour and tocolysis. Fetal Matern Med Rev 1998;10:121-36.

23. Zoumakis E, Makrigiannakis A, Margioris AN, Stournaras C, Gravanis A. Endometrial corticotropin-releasing hormone. its potential autocrine and paracrine actions. Ann NY Acad Sci 1997;828:84-94.

24. Petraglia F, Potter E, Cameron VA, Sutton S, Behan DP, Woods RJ, et al. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J Clin Endocrinol Metab 1993;77:919-24.

25. Jones SA, Brooks AN, Challis JR. Steroids modulate corticotropin-releasing hormone production in human fetal membranes and placenta. J Clin Endocrinol Metab 1989;68:825-30.

26. Petraglia F, Coukos G, Volpe A, Genazzani AR, Vale W. Involvement of placental neurohormones in human parturition. Ann NY Acad Sci 1991;622:331-40.

27. Smith R, Mesiano S, Chan EC, Brown S, Jaffe RB. Corticotropin-releasing hormone directly and preferentially stimulates dehydroepiandrosterone sulfate secretion by human fetal adrenal cortical cells. J Clin Endocrinol Metab 1998;83:2916-20.

28. Chakravarty A, Mesiano S, Jaffe RB. Corticotropin-releasing hormone stimulates P450 17 alpha-hydroxylation/17,20-lyase in human fetal adrenal cells via protein kinase C. J Clin Endocrinol Metab 1999;84:3732-8.

29. Lockwood CJ, Radunovic N, Nastic D, Petkovic S, Aigner S, Berkowitz GS. Corticotropin-releasing hormone and related pituitary-adrenal axis hormones in fetal and maternal blood during the second half of pregnancy. J Perinat Med 1996;24:243-51.

30. Perkins AV, Eben F, Wolfe CD, Schulte HM, Linton EA. Plasma measurements of corticotrophin-releasing hormone-binding protein in normal and abnormal human pregnancy. J Endocrinol 1993;138:149-57.

31. Nathanielsz PW. Comparative studies on the initiation of labour. Eur J Obstet Gynecol Reprod Biol 1998;78:127-32.

32. Giassani DA, Jenkins SL, Meenar CA, Winter JA, Horneber BO, Wu W, et al. Daily and hourly temporal association between delta4-androstenedione-induced preterm myometrial contractions and maternal plasma estradiol and oxytocin concentrations in the 0.8 gestation rhesus monkey. Am J Obstet Gynecol 1996;174:1050-5.

33. Nathanielsz PW, Jenkins SL, Tame JD, Winter JA, Guller S, Giassani DA. Local paracrine effects of estradiol are central to parturition in the rhesus monkey. Nat Med 1998;4:456-9.

34. Gibb W. The role of prostaglandins in human parturition. Ann Med 1998;30:235-41.

35. Grammatopoulos DK, Hillhouse EW. Role of corticotropin-releasing hormone in onset of labor. Lancet 1999;354:1546-9.

36. Chwalisz K, Garfield RE. Role of nitric oxide in the uterus and cervix: Implications for the management of labor. J Perinat Med 1998;26:448-57.

37. Jones SA, Brooks AN, Challis JR. Steroids modulate corticotropin releasing factor production in human fetal membranes and placenta. J Clin Endocrinol Metab 1998;68:825-30.

38. Jones SA, Challis JR. Steroid, corticotrophin-releasing hormone, ACTH and prostaglandin interactions in the amnion and placenta of early pregnancy in man. J Endocrinol 1990;125:150-9.

39. Petraglia F, Florio F, Nappio C, Genazzani AR. Peptide signaling in the human placenta and membranes: autocrine, paracrine and endocrine mechanisms. Endocr Rev 1996;17:156-86.

40. Fuchs AR, Fuchs F. Endocrinology of term and preterm labor. In: Fuchs AR, Fuchs F, Stablefield P, editors. Preterm birth – causes, prevention and management. 2nd ed. New York: McGraw Hill; 1993. p. 59.

41. Jackson M, Dudley DJ. Endocrine assays to predict preterm delivery. Clin Perinat 1998;4:837-57.

42. Petrocelli T, Lyu SJ. Regulation of transcripts encoding the myometrial gap junction protein, connexin-43, by estrogen and progesterone. Endocrinology 1993;133:284-90.

43. Lyu SJ, Nicholson BJ, Mascalenas M, MacKenzie L, Petrocelli T. Increased expression of connexin-43 in the rat myometrium during labour is associated with an increase in the plasma estrogen: Progesterone ratio. Endocrinology 1993;132:2380-6.

44. Bale TL, Dorsa DM. Cloning, novel promoter sequence, and estrogen regulation of a rat oxytocin receptor gene. Endocrinology 1997;138:1151-8.

45. Windmoller R, Lyu SJ, Challis JR. Estradiol modulation of ovine uterine activity. Can J Physiol Pharmacol 1983;61:722-8.

46. Matsui K, Higashi K, Fukunaga K, Miyazaki K, Maejima Y, Miyamoto E. Hormone treatments and pregnancy alter myosin light chain kinase and calmodulin levels in rabbit myometrium. J Endocrinol 1983;97:11-9.

47. Madsen G, Zakar T, Ku CY, Sanborn BM, Smith R, Mesiano S. Prostaglandins differentially modulate progesterone receptor-A and -B expression in human myometrial cells: Evidence for progaglandin-induced functional progesterone withdrawal. J Clin Endocrinol Metab 2004;89:1010-3.

48. Grazini E, Guilion G, Mouillac B, Zingg HH. Inhibitions of oxytocin receptor function by direct binding of progesterone. Nature 1998;392:509-12.

49. Condon JC, Jeyasuria P, Faust JM, Wilson JW, Mendelson CR. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize progesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci USA 2003;100:9518-23.

50. Keine MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynaecol 1990;97:149-54.

51. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.

52. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419-24.

53. Leppert PC. Cervical softening, effacement and dilatation in a complex biochemical cascade. J Matern Fetal Med 1992;1:213-23.

54. Mitchell BF, Wong S. Changes in 17 beta,20 alpha-hydroxyprogesterone dehydrogenase activity supporting an increase in the estrogen/progesterone ratio of human fetal membranes at parturition. Am J Obstet Gynecol 1993;168:1377-85.

55. Challis JR, Sloboda DM, Alfaiadi N, Lyu SJ, Gibb W, Patel FA, et al. Prostaglandins and mechanisms of preterm birth. Reproduction 2002;124:1-17.

56. Karalis K, Goodwin G, Majzoub JA. Cortisol blockade of progesterone: A possible molecular mechanism involved in the initiation of human labour. Nat Med 1996;2:556-60.
Kota, et al.: Parturition

57. Gibb W. The role of prostaglandins in human parturition. Ann Med 1998;30:235-41.
58. Gross G, Imamura T, Muglia LJ. Gene knockout mice in the study of parturition. J Soc Gynecol Investig 2000;7:88-95.
59. Olson DM, Skinner K, Challis JR. Prostaglandin output in relation to parturition by cells dispensed from human intrauterine tissues. J Clin Endocrinol Metab 1983;57:694-9.
60. Skinner KA, Challis JR. Change is the synthesis and metabolism of prostaglandins by human fetal membranes and decidua in labor. Am J Obstet Gynecol 1985;151:519-23.
61. Falcone T, Little AB. Placental synthesis of steroid hormones. In: Tulchinsky D, Little AB editors. Maternal-fetal endocrinology, 2nd ed. Philadelphia: WB Saunders Co; 1994. p. 10-4.
62. Olson DM, Skinner K, Challis JR. Estradiol-17 beta and 2-hydroxyestradiol-17 beta-induced differential production of prostaglandins by cells dispersed from human intrauterine tissues at parturition. Prostaglandins 1983;25:639-51.
63. Smith SK, Kelly RW. The effect of the antiprogestins RU 486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2 alpha and E2 in separated cells from early human decidua. J Clin Endocrinol Metab 1987;65:527-34.
64. Siler-Khodr TM, Kang IS, Koong MK. Dose-related action of estradiol on placental prostaglandin prediction. Prostaglandins 1996;51:387-401.
65. Ishihara O, Matsuoka K, Kinoshita K, Sullivan MH, Elder MG. Interleukin-1 beta-stimulated PGE2 production from early first trimester human decidual cells is inhibited by dexamethasone and progesterone. Prostaglandins 1995;49:15-26.
66. Pomin F, Caruso A, Challis JR. Interleukin-10 modifies the effects of interleukin-1 beta and tumor necrosis factor-alpha on the activity and expression of prostaglandin H synthase-2 and the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in cultured term human villous trophoblast and chorion trophoblast cells. J Clin Endocrinol Metab 1999;84:4645-51.
67. Leake RD, Weitzman RE, Glatz TH, Fisher DA. Plasma oxytocin concentrations in men, nonpregnant women, and pregnant women before and during spontaneous labor. J Clin Endocrinol Metab 1981;53:730-3.
68. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984;150:734-41.
69. Adachi S, Oku M. The regulation of oxytocin receptor expression in human myometrial monolayer culture. J Smooth Muscle Res 1995;31:175-87.
70. Chan WY, Powell AM, Hruby VJ. Antioxytocic and antiprostaglandin-releasing effects of oxytocin antagonists in pregnant rats and pregnant human myometrial strips. Endocrinology 1982;111:48-54.
71. Carsten ME, Miller JD. A new look at uterine muscle contraction. Am J Obstet Gynecol 1987;157:1303-15.
72. Rivera J, López Bernal A, Varney M, Watson SP. Inositol 1,4,5-trisphosphate and oxytocin binding in human myometrium. Endocrinology 1990;127:155-62.
73. Chibbar R, Miller FD, Mitchell BE. Synthesis of oxytocin in amnion, chorion, and decidua may influence the timing of human parturition. J Clin Invest 1993;91:185-92.
74. Weiss G, Goldsmith LT. Relaxin. In: Adashi EY, Rock JA, Rosenwaks Z editors. Reproductive endocrinology, surgery and technology. chapter 39. Philadelphia: Lippincott-Raven; 1996. p. 827-39.
75. Palejwala S, Stein D, Wojtczuk A, Weiss G, Goldsmith LT. Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment firoblasts. Endocrinology 1998;139:1208-12.
76. Goldsmith LT, Weiss G, Palejwala S. The role of relaxin in preterm labor. Prenat Neonat Med 1998;3:109-12.
98. Weiss G. Endocrinology of parturition. J Clin Endocrinol Metab 2000;85:4421-5.
99. Goodwin TM. A role for estriol in human labor, term and preterm. Am J Obstet Gynecol 1999;180:S208-13.
100. Petersen LK, Skajaa K, Ulldbjerg N. Serum relaxin is a potential marker of preterm labor. Br J Obstet Gynecol 1992;99:292-5.
101. Mogren I, Stenlund H, Högberg U. Recurrence of prolonged pregnancy. Int J Epidemiol 1999;28:253-7.
102. Divon MY, Ferber A, Nisell H, Westgren M. Male gender predisposes to prolongation of pregnancy. Am J Obstet Gynecol 2002;187:1081-3.
103. Smith GC. Life-table analysis of the risk of perinatal death at term and post term in singleton pregnancies. Am J Obstet Gynecol 2001;184:489-96.
104. Treger M, Hallak M, Silberstein T, Friger M, Katz M, Mazor M. Post-term pregnancy: Should induction of labour be considered before 42 weeks? J Matern Fetal Neonatal Med 2002;11:50-3.
105. Cotzias CS, Paterson-Brown S, Fisk NM. Prospective risk of unexplained stillbirth in singleton pregnancies at term: Population based analysis. BMJ 1999;319:287-8.
106. Rand L, Robinson JN, Economy KE, Norwitz ER. Post-term induction of labour revisited. Obstet Gynecol 2000;96:779-83.
107. Badawi N, Kurinczuk JJ, Keogh JM, Alessandri LM, O’Sullivan F, Burton PR, et al. Antepartum risk factors for newborn encephalopathy: The Western Australian case-control study. BMJ 1998;317:1549-53.
108. ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin. Clinical management guidelines for obstetricians-gynecologists. Number 55, September 2004 (replaces practice pattern number 6, October 1997). Management of Postterm Pregnancy. Obstet Gynecol 2004;104:639-46.

Cite this article as: Kota SK, Gayatri K, Jammula S, Kota SK, Krishna SVS, Meher LK, et al. Endocrinology of parturition. Indian J Endocr Metab 2013;17:50-9.

Source of Support: Nil, Conflict of Interest: None declared.